Published online August 31, 2005
PEDIATRICS Vol. 116 No. 3 September 2005, pp. 767-770 (doi:10.1542/10.1542/peds.2005-0806)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fullmer, J. J.
Right arrow Articles by Krance, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fullmer, J. J.
Right arrow Articles by Krance, R.
Related Collections
Right arrow Tumors
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

EXPERIENCE AND REASON

Successful Treatment of Bronchiolitis Obliterans in a Bone Marrow Transplant Patient With Tumor Necrosis Factor-{alpha} Blockade

Jason J. Fullmer, MD*, Leland L. Fan, MD*, Megan K. Dishop, MD{ddagger}, Cheryl Rodgers, RNP§ and Robert Krance, MD§

* Pulmonary Medicine
{ddagger} Pathology
§ Hematology and Oncology, Department of Pediatrics, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas

Bronchiolitis obliterans (BO) in children is a rare, inflammatory/fibrosing process involving the small airways that often results in progressive, irreversible obstructive pulmonary disease. Because treatment has focused mainly on supportive care and generally unsuccessful immunosuppression, children with BO experience significant morbidity and mortality. We report a case of biopsy-proven BO after bone marrow transplantation in a child who, after failed corticosteroid therapy, was treated with infliximab, a monoclonal antibody with binding specificity for human tumor necrosis factor-{alpha}. With initiation of treatment, her pulmonary symptoms and radiographic and spirometric evidence of BO resolved. Nine months later, she remains asymptomatic and shows no evidence of pulmonary decompensation. This case illustrates a successful treatment of BO with selective tumor necrosis factor-{alpha} blockade.

Key Words: bone marrow transplant • bronchiolitis obliterans • tumor necrosis factor-alpha

Abbreviations: BO, bronchiolitis obliterans • BMT, bone marrow transplantation • TNF-{alpha}, tumor necrosis factor-{alpha} • GVHD, graft-versus-host disease • HRCT, high-resolution computed tomography • IVIG, intravenous immunoglobulin • RSV, respiratory syncytial virus • FEV1, forced expiratory volume in 1 second • IL, interleukin

Accepted May 18, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Psychiatr. Serv.Home page
K. T. Mueser and J. Taub
Trauma and PTSD Among Adolescents With Severe Emotional Disorders Involved in Multiple Service Systems
Psychiatr Serv, June 1, 2008; 59(6): 627 - 634.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
K J Smith and L L Fan
Insights into post-infectious bronchiolitis obliterans in children.
Thorax, June 1, 2006; 61(6): 462 - 463.
[Full Text] [PDF]